Bernstein Liebhard LLP Publishes New GranuFlo Lawsuit Website for Individuals Allegedly Affected by 2012 Dialysis Drug Recall

Share Article

The Firm is offering free and confidential GranuFlo lawsuit evaluations to individuals who may have experienced strokes, heart attacks, cardiopulmonary arrest and other heart-related problems allegedly caused by the dialysis drug.

Free Case Review
Our Firm understands the importance of creating a website that educates individuals who may have been affected by last year’s GranuFlo recall.

Bernstein Liebhard LLP has launched a new NaturaLyte and GranuFlo lawsuit ( website for patients who allegedly sustained the serious cardiovascular injuries now associated with these dialysis medications, and may now be eligible to file a claim, the Firm reports.

Included on the new site will be information pertaining to the Class I recall of NaturaLyte and GranuFlo, which was issued by the U.S. Food and Drug Administration (FDA) in June 2012. According to hundreds of cases that have already been filed, the risk for strokes, heart attacks, sudden cardiac death and other injuries may follow use of GranuFlo and NaturaLyte, and are allegedly experienced within 72 hours of their administration. The Firm’s new site will also include updates in a federal GranuFlo lawsuit litigation underway in the U.S. District Court, District of Massachusetts, as they continue to develop. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)

“Our Firm understands the importance of creating a website that educates individuals who may have been affected by last year’s GranuFlo recall about whether they may be eligible to file a claim,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs like GranuFlo. The Firm is offering free and confidential case evaluations to those who may have experienced side effects stemming from these medications.

GranuFlo Lawsuits

Court records indicate that federally-filed GranuFlo lawsuit claims are continuing to move forward in the federal litigation underway in Massachusetts. According to a Case List update from the U.S. Judicial Panel on Multidistrict Litigation, a total of 433 claims alleging injuries caused by the acid concentrates, which are used during dialysis treatments, had been filed in the proceeding as of December 16th.

As the Case List in this litigation continues to grow, an order recently issued by a federal judge overseeing the proceeding indicates that the process for selecting bellwether trials is now underway. According to court documents, parties have been directed to submit a Case Management Order addressing this matter, as well as case specific discovery, by January 6, 2014.

A number of GranuFlo and NaturaLyte lawsuits have also been filed in a consolidated litigation established in Massachusetts’ Middlesex County Superior Court. (In re: Consolidated Fresenius Cases, No. MICV2013-03400-O)

These lawsuits similarly allege that Fresenius Medical Care, a leading supplier of dialysis products and services in the U.S., failed to adequately warn dialysis patients and their doctors about the serious injuries that may stem from use of its products. Plaintiffs in these cases also point to an internal memo sent by the company in November 2011 that warned doctors operating in its clinics that 941 deaths had occurred in individuals who were given GranuFlo and/or NaturaLyte. According to a New York Times report published in the summer of 2012, physicians operating at commercial clinics outside the Fresenius network were not warned about the medications’ association with serious heart problems until March 2012, when an Urgent Product Notification was issued by the company.* The Times further states that the FDA had begun to investigate whether the company violated federal law in its failure to disclose this information before then.

If you or a loved one suffered the serious heart problems associated with GranuFlo and NaturaLyte within 72 hours of receiving the medications, you may be eligible to file a claim against Fresenius. Learn more about the GranuFlo recall by visiting Bernstein Liebhard LLP’s website. To arrange for a free case review, please call 800-511-5092.

*; New York Times, June 14, 2012

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this
advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Follow us on
Visit website